Performance of Subgenomic RT‐PCR for Predicting SARS‐CoV‐2 Infectivity Compared to Genomic RT‐PCR and Culture Isolation
Journal of Medical Virology · 2025
DOI: 10.1002/jmv.70363 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Célia Sentis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospices Civils de Lyon, Institut des Agents Infectieux, service de Virologie, Laboratoire Associé au Centre National de Référence des Virus des Infe…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, COVID-19 Nucleic Acid Testing, Reverse Transcriptase Polymerase Chain Reaction. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
SARS‐CoV‐2 clinical samples can be detected as positive for a long period of time using real‐time RT‐PCR, even when patients are no longer infectious. Viral culture is the gold standard for assessing a patient's infectivity, but it is a time‐consuming technique and lacks sensitivity. SARS‐CoV‐2 subgenomic RNA (sgRNA) detection has been used as a proxy for assessing the infectivity but only a limited number of studies have described its use in vitro and in clinical samples. This study aimed to evaluate the correlation between results from viral culture, genomic RT‐PCR (gRT‐PCR), and subgenomic RT‐PCR (sgRT‐PCR) during in vitro infection and in clinical samples. In vitro viral replication kinetics showed that both genomic RNA (gRNA) and subgenomic RNA (sgRNA) levels remained stable up to 21 days in the absence of replication‐competent virus. Using clinical samples, sgRNA was detected in 87.5% of culture‐positive samples, demonstrating better performances than gRT‐PCR (Positive predictive value (PPV) 93.3% and Negative predictive value (NPV) of 87.5%) and an almost perfect agreement with culture results (Cohen κ = 0.81 [95% CI: 0.66–0.95]). These findings suggest that testing for sgRNA and/or using a gRNA Ct cut‐off of 21.2 could be used as a proxy to determine the presence of SARS‐CoV‐2 replication‐competent virus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospices Civils de Lyon, Institut des Agents Infectieux, service de Virologie, Laboratoire Associé au Centre National de Référence des Virus des Infections Respiratoires, Lyon, France.
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, Lyon, France.
ORCID-Profile: Célia Sentis
Zitieren
APA
Sentis, C., Parraud, D., Billaud, G., Valette, M., Bouscambert-Duchamp, M., Lina, B., Morfin, F., & Gaymard, A. (2025). Performance of Subgenomic RT‐PCR for Predicting SARS‐CoV‐2 Infectivity Compared to Genomic RT‐PCR and Culture Isolation. Journal of Medical Virology. https://doi.org/10.1002/jmv.70363
Vancouver
Sentis C, Parraud D, Billaud G, Valette M, Bouscambert-Duchamp M, Lina B, et al. Performance of Subgenomic RT‐PCR for Predicting SARS‐CoV‐2 Infectivity Compared to Genomic RT‐PCR and Culture Isolation. Journal of Medical Virology. 2025. doi:10.1002/jmv.70363
BibTeX
@article{Sentis2025,
author = {Sentis, Célia and Parraud, Delphine and Billaud, Geneviève and Valette, Martine and Bouscambert-Duchamp, Maude and Lina, Bruno and Morfin, Florence and Gaymard, Alexandre},
title = {Performance of Subgenomic RT‐PCR for Predicting SARS‐CoV‐2 Infectivity Compared to Genomic RT‐PCR and Culture Isolation},
journal = {Journal of Medical Virology},
year = {2025},
doi = {10.1002/jmv.70363}
}
EUVIMED